InvestorsHub Logo
Followers 8
Posts 443
Boards Moderated 0
Alias Born 03/25/2016

Re: None

Tuesday, 06/14/2016 7:52:39 AM

Tuesday, June 14, 2016 7:52:39 AM

Post# of 232910
CytoDyn's PRO 140: A Paradigm Shift in the $20 Billion HIV Market

NEW YORK, NY / ACCESSWIRE / June 13, 2016 / Rising Tide Equity Research, LLC announced today the release of its Initial Equity Report on CytoDyn (OTCQB: CYDY), a biotechnology company focused on the development of monoclonal antibodies for the treatment of human immunodeficiency virus (HIV) and Graph versus Host Disease (GvHD). The Company's lead clinical candidate, PRO 140, is currently in two Phase 3 trials evaluating its effectiveness as an adjunct therapy to current HIV treatment and as a monotherapy treatment for HIV.

Full article can be found on Accesswire.com
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News